Technical University of Munich spin-out ImevaX partners with Project Pharmaceuticals on stomach pain.
ImevaX, a biotech spin-out of the Technical University of Munich, has announced plans to partner with Germany-based Project Pharmaceuticals on tackling stomach pain caused by bacterium. Specifically, the two companies are targeting a microaerophilic bacterium known as Helicobacter pylori. While up to 85% of people infected with H. pylori never experience complications, it has been…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
